Abstract
The t(4;11)(q21;q23) fuses mixed-lineage leukemia (MLL) to AF4, the most common MLL-fusion partner. Here we show that MLL fused to murine Af4, highly conserved with human AF4, produces high-titer retrovirus permitting efficient transduction of human CD34+ cells, thereby generating a model of t(4;11) pro-B acute lymphoblastic leukemia (ALL) that fully recapitulates the immunophenotypic and molecular aspects of the disease. MLL-Af4 induces a B ALL distinct from MLL-AF9 through differential genomic target binding of the fusion proteins leading to specific gene expression patterns. MLL-Af4 cells can assume a myeloid state under environmental pressure but retain lymphoid-lineage potential. Such incongruity was also observed in t(4;11) patients in whom leukemia evaded CD19-directed therapy by undergoing myeloid-lineage switch. Our model provides a valuable tool to unravel the pathogenesis of MLL-AF4 leukemogenesis.
Original language | English (US) |
---|---|
Pages (from-to) | 737-749 |
Number of pages | 13 |
Journal | Cancer Cell |
Volume | 30 |
Issue number | 5 |
DOIs | |
State | Published - Nov 14 2016 |
Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2016 Elsevier Inc.
Keywords
- MLL-AF4
- acquired resistance to targeted therapy
- acute lymphoblastic leukemia
- chimeric fusion proteins
- mouse models of cancer
- species specificity of oncogenes